Acute pulmonary embolism: An unseen villain in COVID-19

Agstam, Sourabh; Vijay, Jyothi; Gupta, Anunay

doi:10.1016/j.ihj.2020.05.003

Cited by 4 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cardiovascular manifestations of SARS-CoV-1 can be attributed either to direct viral injury or to an immunological response to the virus, as we see in myocarditis 24 25 ( Fig. 2 ).…”

Section: Covid-19 and Cardiovascular Risk Factorsmentioning

confidence: 82%

“…APLA, antiphospholipid antibodies; IL, interleukin; IFN-γ, interferon-gamma; MCP, monocyte chemoattractant protein; TNF-α, tumour necrosis factor-alpha. Source : Refs 24 25 .…”

Section: Covid-19 and Cardiovascular Risk Factorsmentioning

confidence: 99%

“…Echocardiography and CT pulmonary angiography could be performed after a complete evaluation of symptoms, and a strong suspicion of PE. D-dimers are usually raised due to the cytokine storm in COVID-19 and will not help in diagnosing PE 25 .…”

Section: Cardiovascular Manifestations Of Covid-19mentioning

confidence: 99%

See 2 more Smart Citations

Cardiovascular manifestations of COVID-19: An evidence-based narrative review

et al. 2021

Self Cite

View full text Add to dashboard Cite

“…The cardiovascular manifestations of SARS-CoV-1 can be attributed either to direct viral injury or to an immunological response to the virus, as we see in myocarditis 24 25 ( Fig. 2 ).…”

Section: Covid-19 and Cardiovascular Risk Factorsmentioning

confidence: 82%

“…APLA, antiphospholipid antibodies; IL, interleukin; IFN-γ, interferon-gamma; MCP, monocyte chemoattractant protein; TNF-α, tumour necrosis factor-alpha. Source : Refs 24 25 .…”

Section: Covid-19 and Cardiovascular Risk Factorsmentioning

confidence: 99%

See 1 more Smart Citation

Cardiovascular manifestations of COVID-19: An evidence-based narrative review

et al. 2021

Self Cite

View full text Add to dashboard Cite

“…Of the 8,028 patients for whom data was reported, 39% had one or more comorbidities, including hypertension (21%), diabetes (12%), cardiovascular disease (9%) and cerebrovascular diseases (6%). In a study of 4,103 COVID-19 patients in a single academic health system in NYC [170], the median age was 52 years and 51% were male; 15% had diabetes, 27% obesity and 30% cardiovascular disease. In the same study, comorbidities were found to be a powerful predictor of COVID-19-associated hospitalization.…”

Section: Demographics Of Covid-19 Patientsmentioning

confidence: 99%

Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection

Labò

Ohnuki

Tosato

2020

Cells

View full text Add to dashboard Cite

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has resulted in >500,000 deaths worldwide, including >125,000 deaths in the U.S. since its emergence in late December 2019 and June 2020. Neither curative anti-viral drugs nor a protective vaccine is currently available for the treatment and prevention of COVID-19. Recently, new clinical syndromes associated with coagulopathy and vasculopathy have emerged as a cause of sudden death and other serious clinical manifestations in younger patients infected with SARS-CoV-2 infection. Angiotensin converting enzyme 2 (ACE2), the receptor for SARS-CoV-2 and other coronaviruses, is a transmembrane protein expressed by lung alveolar epithelial cells, enterocytes, and vascular endothelial cells, whose physiologic role is to induce the maturation of angiotensin I to generate angiotensin 1-7, a peptide hormone that controls vasoconstriction and blood pressure. In this review, we provide the general context of the molecular and cellular mechanisms of SARS-CoV-2 infection with a focus on endothelial cells, describe the vasculopathy and coagulopathy syndromes in patients with SARS-CoV-2, and outline current understanding of the underlying mechanistic aspects.

show abstract

“…Pulmonary embolism (PE) is the mortality leading cause of death in COVID-19 26 . The cumulative incidence of PE was 20.6 and 23 per cent in two different case series from Italy 27 .…”

Section: Coagulation Abnormalities In Covid-19mentioning

confidence: 99%

Coagulation abnormalities & thromboprophylaxis in COVID-19

Jandial¹,

Gupta

Malviya

et al. 2021

Indian J Med Res

Self Cite

View full text Add to dashboard Cite

The ongoing pandemic of novel coronavirus 2019 is rapidly evolving, and newer organ- and system-specific manifestations are being observed. Thrombotic complications and coagulopathy are frequent manifestations of the disease, especially in sick patients, which appear to be unique and distinct from sepsis-induced coagulopathy, disseminated intravascular coagulation and other viral infection-induced coagulation abnormalities. Elevated D-dimers and fibrinogen in the early stage of the disease with minimally deranged prothrombin time and platelet counts are prominent and distinguishing features. Venous and arterial thromboses, as opposed to bleeding events, are the major clinical correlates. There is much to be known about the pathogenesis of COVID-associated coagulopathy; however, the mechanisms overlap with thrombotic microangiopathy, haemophagocytic syndrome and antiphospholipid syndrome compounded by the diffuse endothelial damage. The recommendations regarding the treatment are still evolving, but antithrombotic therapy has a definite role in positive outcomes of sick patients.

show abstract

Acute pulmonary embolism: An unseen villain in COVID-19

Cited by 4 publications

References 8 publications

Cardiovascular manifestations of COVID-19: An evidence-based narrative review

Cardiovascular manifestations of COVID-19: An evidence-based narrative review

Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection

Coagulation abnormalities & thromboprophylaxis in COVID-19

Contact Info

Product

Resources

About